

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/511,661	10/18/2004	Conrad P. Dorn	21058YP	4903
210 MERCK AND	7590 08/07/2007 CO INC	,	EXAMINER	
P O BOX 2000			O SULLIVAN, PETER G	
RAHWAY, NJ 07065-0907			ART UNIT	PAPER NUMBER
			1621	
			MAIL DATE	DELIVERY MODE
			08/07/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/511,661	DORN ET AL.			
Office Action Summary	Examiner	Art Unit			
	Peter G. O'Sullivan	1621			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tin vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C.§ 133).			
Status	•				
1) Responsive to communication(s) filed on					
•	action is non-final.	•			
· <u> </u>					
closed in accordance with the practice under E	•				
Disposition of Claims					
4)⊠ Claim(s) <u>1-11</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdraw					
5) Claim(s) is/are allowed.		•			
6)☐ Claim(s) is/are rejected.					
7) Claim(s) is/are objected to.					
8)⊠ Claim(s) <u>1-11</u> are subject to restriction and/or e	election requirement.				
Application Papers					
9) The specification is objected to by the Examine	<b>r.</b>				
10) The drawing(s) filed on is/are: a) acce	epted or b) $\square$ objected to by the $\mathfrak l$	Examiner.			
. Applicant may not request that any objection to the o	drawing(s) be held in abeyance. See	∋ 37 CFR 1.85(a).			
Replacement drawing sheet(s) including the correcti	on is required if the drawing(s) is ob	ected to. See 37 CFR 1.121(d).			
11) ☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:	priority under 35 U.S.C. § 119(a)	-(d) or (f).			
1.☐ Certified copies of the priority documents	s have been received.				
2. Certified copies of the priority documents		on No			
<ol><li>Copies of the certified copies of the prior</li></ol>	ity documents have been receive	ed in this National Stage			
application from the International Bureau	(PCT Rule 17.2(a)).				
* See the attached detailed Office action for a list of	of the certified copies not receive	: <b>d.</b> .			
•	• ()	•			
·		•			
Attachment(s)	•				
1) Notice of References Cited (PTO-892)	4) Interview Summary				
2)  Notice of Draftsperson's Patent Drawing Review (PTO-948) 3)  Information Disclosure Statement(s) (PTO/SB/08)	Paper No(s)/Mail Da 5) Notice of Informal P				
Paper No(s)/Mail Date	6) Other:	· #F···-·····			

Application/Control Number: 10/511,661

Art Unit: 1621

Restriction to one of the following inventions is required under 35 U.S.C. 121:

I. Claims 1-8, drawn to aminoalkylphenols, classified in class 564, subclass 355+.

II. Claims 9-11, drawn to methods of treating malaria with aminoalkylphenols or combinations with other anti-malarial agents, classified in class 514, subclass 311+.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product. See MPEP § 806.05(h). In the instant case the instant compounds could be used as anti-oxidants. Additionally, the treatment of malaria with pharmaceutical combinations is outside of the scope of the compounds of claim 1.

Because these inventions are independent or distinct for the reasons given above and there would be a serious burden on the examiner if restriction is not required because the inventions have acquired a separate status in the art due to their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicants are further required to elect a single disclosed species, i.e. a
single disclosed compound if group I is elected or a single disclosed compound
or combination of compounds if group II is elected.

Application/Control Number: 10/511,661 Page 3

Art Unit: 1621

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Any inquiry concerning this communication should be directed to Peter G. O'Sullivan at telephone number (571)272-0642.

PETER O'S CELIVAN PRIMARY EXAMINER GROUP 1200